Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (NASDAQ:SRPT) has announced equity awards granted to 39 new employees hired in Q1 2025 under its 2024 Employment Commencement Incentive Plan. The grants, approved by the Compensation Committee and compliant with Nasdaq Listing Rule 5635(c)(4), include:
- 31,344 stock options with an exercise price of $63.82 per share
- 77,442 restricted stock units (RSUs)
The stock options will vest over four years, with 25% vesting after one year and the remaining vesting monthly at 1/48th. RSUs will vest annually at 25% over four years. Both are subject to continued employment.
Sarepta Therapeutics (NASDAQ:SRPT) ha annunciato l'assegnazione di premi azionari a 39 nuovi dipendenti assunti nel primo trimestre del 2025 nell'ambito del suo Piano di Incentivo per l'Inizio dell'Occupazione 2024. I premi, approvati dal Comitato per la Compensazione e conformi alla Regola di Quotazione Nasdaq 5635(c)(4), includono:
- 31.344 opzioni azionarie con un prezzo di esercizio di $63.82 per azione
- 77.442 unità azionarie vincolate (RSU)
Le opzioni azionarie matureranno in quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente a 1/48. Le RSU matureranno annualmente al 25% per quattro anni. Entrambi sono soggetti a continuazione dell'impiego.
Sarepta Therapeutics (NASDAQ:SRPT) ha anunciado la concesión de premios en acciones a 39 nuevos empleados contratados en el primer trimestre de 2025 bajo su Plan de Incentivo para el Inicio del Empleo 2024. Las concesiones, aprobadas por el Comité de Compensación y en conformidad con la Regla de Cotización de Nasdaq 5635(c)(4), incluyen:
- 31,344 opciones de acciones con un precio de ejercicio de $63.82 por acción
- 77,442 unidades de acciones restringidas (RSUs)
Las opciones de acciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el resto consolidándose mensualmente a 1/48. Las RSUs se consolidarán anualmente al 25% durante cuatro años. Ambos están sujetos a la continuidad del empleo.
사레프타 테라퓨틱스 (NASDAQ:SRPT)는 2025년 1분기에 채용된 39명의 신규 직원에게 2024 고용 시작 인센티브 계획에 따라 주식 보상을 부여한다고 발표했습니다. 이 보상은 보상 위원회에 의해 승인되었으며, 나스닥 상장 규칙 5635(c)(4)에 부합합니다. 포함된 내용은 다음과 같습니다:
- 주당 $63.82의 행사 가격으로 31,344개의 스톡 옵션
- 77,442개의 제한 주식 단위 (RSU)
스톡 옵션은 4년에 걸쳐 베스팅되며, 1년 후 25%가 베스팅되고 나머지는 월별로 1/48씩 베스팅됩니다. RSU는 4년에 걸쳐 매년 25%씩 베스팅됩니다. 두 가지 모두 고용 지속에 따라 달라집니다.
Sarepta Therapeutics (NASDAQ:SRPT) a annoncé l'octroi de récompenses en actions à 39 nouveaux employés embauchés au premier trimestre 2025 dans le cadre de son Plan d'Incentive pour le Début de l'Emploi 2024. Les octrois, approuvés par le Comité de Rémunération et conformes à la Règle de Cotation Nasdaq 5635(c)(4), comprennent :
- 31 344 options d'achat d'actions avec un prix d'exercice de $63.82 par action
- 77 442 unités d'actions restreintes (RSU)
Les options d'achat d'actions deviendront acquises sur quatre ans, avec 25 % devenant acquises après un an et le reste acquérant mensuellement à 1/48. Les RSU deviendront acquises annuellement à 25 % sur quatre ans. Les deux sont soumis à la continuité de l'emploi.
Sarepta Therapeutics (NASDAQ:SRPT) hat die Gewährung von Aktienprämien an 39 neue Mitarbeiter bekannt gegeben, die im ersten Quartal 2025 im Rahmen seines 2024 Beschäftigungsbeginn-Incentive-Plans eingestellt wurden. Die Gewährungen, die vom Vergütungsausschuss genehmigt wurden und den Nasdaq-Listing-Regeln 5635(c)(4) entsprechen, umfassen:
- 31.344 Aktienoptionen mit einem Ausübungspreis von $63.82 pro Aktie
- 77.442 beschränkte Aktieneinheiten (RSUs)
Die Aktienoptionen werden über vier Jahre fällig, wobei 25 % nach einem Jahr fällig werden und der Rest monatlich zu 1/48. Die RSUs werden jährlich über vier Jahre zu 25 % fällig. Beide unterliegen der Fortsetzung der Beschäftigung.
- Continued workforce expansion with 39 new hires in Q1 2025
- Implementation of employee retention strategy through long-term equity incentives
- Potential dilution of existing shareholders from new equity grants
- Increased stock-based compensation expenses
The employees received, in the aggregate, options to purchase 31,344 shares of Sarepta's common stock, and in the aggregate 77,442 restricted stock units (“RSUs”). The options have an exercise price of
One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331242323/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
How many shares were granted in Sarepta's (SRPT) Q1 2025 equity awards?
What is the exercise price for SRPT's March 2025 stock options?
What is the vesting schedule for Sarepta's March 2025 equity awards?
How many new employees received SRPT equity awards in Q1 2025?
